Clinical Trial Update: Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating conversion to sirolimus versus reduction of calcineurin inhibitors in renal transplant patients with prostate cancer was w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Calcineurin inhibitor (CNI) reduction (calcineurin inhibitor)
• Rapamune (sirolimus)

Snippet

Sponsor: St. Joseph's Healthcare Hamilton | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: WITHDRAWN